Expiration date: 11/2026
The composition and form of issue:
Capsules. 1 capsule contains:
chondroitin sulfate sodium 0.25 g
excipients: lactose (milk sugar) calcium stearate
the composition of the gelatin capsules: titanium dioxide dye azorubin crimson dye (Ponceau 4R) patented blue dye (patent blue V), black diamond dye (brilliant black BN) methyl parahydroxybenzoate (metilgidroksibenzoat) parahydroxybenzoate (propilgidroksibenzoat) acetic acid gelatin
in a contour acheikova packing 10 PCs. in cardboard pack 5 packs or in cans of 20 PCs the paper cartons 1 Bank.
Ointment 5%. 100 g contains:
chondroitin sodium sulfate (calculated as dry substance) 5 g
the Dimexidum (dimethyl sulfoxide) 10 g
excipients (base): anhydrous lanolin, vaseline medical purified water
the aluminium tubes of 30 grams in a cardboard bundle 1 tuba.
Description pharmaceutical form:
Capsules: hard gelatin No. 1, cover — blue, body — blue.
The contents of capsules — powder white or white with a slightly yellowish tint.
Ointment light yellow color with the smell of dimethyl sulfoxide.
Pharmacokinetics:
Capsule: the ingestion of more than 70% chondroitin sulfate is absorbed in the digestive tract. Drug bioavailability is 13%. A single intake of a average therapeutic dose Cmax in plasma observed after 3-4 h, in the synovial fluid — through 4-5 h.
Absorbed in the gastrointestinal tract, the drug accumulates in synovial fluid.
Excreted by the kidneys.
Description pharmacological action:
Capsules. Influences on exchange processes in hyaline and fibrous cartilage, reduces degenerative changes in the cartilage of joints, stimulates biosynthesis of glycosaminoglycans. Slows bone resorption and reduces the loss of calcium, accelerates bone tissue restoration. In the treatment of drug Chondroitin-Agos reduces pain and improves the mobility of affected joints. Therapeutic effect persists for a long time after the end of treatment.
Ointment. Chondroitin-AKOS contains chondroitin sulfate — stimulant recovery of cartilage tissue in joints (cartilage) derived from the trachea cartilage of cattle and dimethylsulfoxide.
Chondroitin sulfate is a mucopolysaccharide of high molecular weight, retarding the processes of destruction of cartilage and accelerate the process of recovery. Inhibits the enzyme, causing the defeat of the cartilage, and prevents its degradation stimulates the biosynthesis of glycosaminoglycans by chondrocytes helps to restore the joint capsule and cartilage surfaces of the joints, increases the production of synovial fluid. Improves calcium and phosphorus metabolism and reduces the loss of calcium in the cartilage tissue, slows the resorption of bone tissue, normalizes metabolism in hyaline tissue, accelerates regeneration (recovery) and slows down the process of degeneration (destruction) of cartilage. Structurally similar to heparin, prevents the formation of fibrin clots in synovial and subchondral microcirculatory bed. The resulting impact reduces pain and increases mobility of the affected joints.
The dimethyl sulfoxide is included in the composition of ointments, anti-inflammatory, analgesic and fibrinolytic action, promotes better penetration of chondroitin sulfate through the cell membrane into tissues.
Ointment Chondroitin-ICCO has analgesic and anti-inflammatory effect, normalizes metabolism and stimulates regeneration processes in the tissues of the joints, leads to a decrease or disappearance of pain in the joints, improve joint mobility and slow the progression of osteoarthritis and degenerative disc disease.
Indications:
Capsules: degenerative diseases of joints and spine: osteoarthritis, osteochondrosis of the spine.
Ointment: treatment and prevention of degenerative disc disease, osteoarthritis peripheral joints and spine.
Contraindications:
For both dosage forms: hypersensitivity to the drug.
For capsules in addition: children up to age 15 years (due to the lack of accurate data).
Caution: bleeding and tendency to bleeding, thrombophlebitis.
For ointment advanced: acute inflammatory processes in the wound area widespread necrotic tissue excessive granulation violation of the integrity of the skin in places of prospective application.
Caution: do not use the ointment Chondroitin-AKOS without consulting a doctor during pregnancy and breastfeeding and in childhood.
Application of pregnancy and breast-feeding:
Capsule: this product is not recommended to appoint in pregnancy and lactation due to the lack of sufficient clinical data.
Ointment: use ointment Chondroitin-ICCO without consulting a doctor during pregnancy and breastfeeding and in childhood.
Side effects:
Capsule: rarely, allergic reactions (urticaria, erythema, pruritus), nausea, vomiting.
Ointment: in rare cases, possible allergic reaction requiring discontinuation of the drug.
Drug interactions:
Capsule: while the use of the drug with other drugs may increase the action of indirect anticoagulants, antiplatelet agents, fibrinolitikov.
Ointment: not known cases of negative drug interactions when assigning ointment during therapy with other drugs, included in the conventional scheme of treatment of degenerative diseases of joints and spine.
Method of application and dose:
Inside, during or after a meal, drinking no less than 1/2 Cup water.
Adults and adolescents 15 years appoint 1 g/day (2 caps. 2 times a day).
The recommended duration of initial treatment is 6 months, the period of action of the drug after its cancellation — 3-5 months depending on the location and stage of the disease, duration of repeated courses of treatment is a doctor.
Externally. Ointment Chondroitin-ICCO applied 2-3 times daily on the skin over the lesion, and rubbed in for 2-3 minutes until fully absorbed. Treatment usually ranges from 2-3 weeks to 2 months. If necessary, repeat the treatment.
Overdose:
Symptoms: in rare cases, possible symptoms of overdose gastrointestinal: nausea, vomiting, diarrhea, prolonged intake of excessively high doses (over 3 g/day) possible hemorrhagic rash.
Treatment: symptomatic.
Special instructions:
Capsule: the caution should appoint patients with bleeding (including history).
Ointment: avoid contact ointments in the mucous membranes and open wounds.
